Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
4 "Sahil Khanna"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Brief Communication
IBD/ Infection
Durability and outcomes of fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with moderate to severe inflammatory bowel disease
Raseen Tariq, Edward V Loftus Jr, Darrell Pardi, Sahil Khanna
Intest Res 2024;22(2):208-212.   Published online January 9, 2024
DOI: https://doi.org/10.5217/ir.2023.00100
PDFSupplementary MaterialPubReaderePub

Citations

Citations to this article as recorded by  
  • Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study
    Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon
    The Korean Journal of Internal Medicine.2024; 39(5): 783.     CrossRef
  • 3,254 View
  • 203 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Reviews
Microbiota
Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
Intest Res 2021;19(4):360-364.   Published online December 1, 2020
DOI: https://doi.org/10.5217/ir.2020.00116
AbstractAbstract PDFPubReaderePub
Immune checkpoint inhibitor therapies such as ipilimumab, are increasingly being used as a treatment option for a variety of cancers, including metastatic melanoma and have demonstrated effectively a prolonged survival. These agents have an immunological mode of action that predisposes patients to a number of immune-related adverse events, colitis being one of the most commonly encountered complications. The pathogenesis for the development of colitis is unclear, and there is a growing consensus that the ecosystem of the gastrointestinal microbiota plays a significant role. Based on this suspected connection, studies are being carried out to explore the changes in the microbiota in patients on these medications who develop colitis. Conceivably, the modulation of the gut microbiota could offer a therapeutic benefit. Fecal microbiota transplantation is one therapeutic option that is currently being investigated, though there are still more data needed to evaluate its efficacy. In this review, we recapitulate the mechanisms of action of immune checkpoint inhibitors, their adverse events, with a focus on colitis and the role gut microbiota are suspected to play, and finally discuss the microbiota modulation therapies being investigated.

Citations

Citations to this article as recorded by  
  • What should intensivists know about immune checkpoint inhibitors and their side effects?
    Viktor Yordanov Zlatkov Aleksandrov, Fernando Martínez Sagasti, Juncal Pérez-Somarriba Moreno, Helena Huertas Mondéjar
    Medicina Intensiva (English Edition).2025; : 502135.     CrossRef
  • Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
    Despoina Chrysostomou, Lauren A. Roberts, Julian R. Marchesi, James M. Kinross
    Gastroenterology.2023; 164(2): 198.     CrossRef
  • Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
    Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi
    Intestinal Research.2023; 21(1): 148.     CrossRef
  • Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis
    Miho Kono, Malek Shatila, Guofan Xu, Yang Lu, Antony Mathew, Wasay Mohajir, Krishnavathana Varatharajalu, Wei Qiao, Anusha S. Thomas, Yinghong Wang
    Cancers.2023; 15(8): 2329.     CrossRef
  • Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy
    Ankita Singh, Sharon Grace Alexander, Sunil Martin
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Gut Microbiome and Colorectal Cancer
    Tae-Geun Gweon
    The Korean Journal of Gastroenterology.2023; 82(2): 56.     CrossRef
  • Impact ofHelicobacter pyloriinfection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
    Patrick T Magahis, Steven B Maron, Darren Cowzer, Stephanie King, Mark Schattner, Yelena Janjigian, David Faleck, Monika Laszkowska
    Journal for ImmunoTherapy of Cancer.2023; 11(10): e007699.     CrossRef
  • Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Kwang Woo Kim
    Gut and Liver.2023; 17(6): 954.     CrossRef
  • MTA1 aggravates experimental colitis in mice by promoting transcription factor HIF1A and up-regulating AQP4 expression
    Ping Li, Dong-Ping Shi, Tao Jin, Dong Tang, Wei Wang, Liu-Hua Wang
    Cell Death Discovery.2022;[Epub]     CrossRef
  • Crosstalk between mucosal microbiota, host gene expression, and sociomedical factors in the progression of colorectal cancer
    Namjoo Kim, Jeong-An Gim, Beom Jae Lee, Byung il Choi, Hee Sook Yoon, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Chungyeul Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Exploration of Potential Gut Microbiota-Derived Biomarkers to Predict the Success of Fecal Microbiota Transplantation in Ulcerative Colitis: A Prospective Cohort in Korea
    Gi-Ung Kang, Sowon Park, Yeongyun Jung, Jai J. Jee, Min-Sueng Kim, Seungjun Lee, Dong-Woo Lee, Jae-Ho Shin, Hong Koh
    Gut and Liver.2022; 16(5): 775.     CrossRef
  • Physical Activity as the Best Supportive Care in Cancer: The Clinician’s and the Researcher’s Perspectives
    Cécile Torregrosa, Frédéric Chorin, Eva Ester Molina Beltran, Cindy Neuzillet, Victoire Cardot-Ruffino
    Cancers.2022; 14(21): 5402.     CrossRef
  • Microbial Modulation in Inflammatory Bowel Diseases
    Jongwook Yu, Jae Hee Cheon
    Immune Network.2022;[Epub]     CrossRef
  • Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
    Liansha Tang, Jialing Wang, Nan Lin, Yuwen Zhou, Wenbo He, Jiyan Liu, Xuelei Ma
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • 6,312 View
  • 296 Download
  • 13 Web of Science
  • 14 Crossref
Close layer
IBD
Management of Clostridioides difficile infection in patients with inflammatory bowel disease
Sahil Khanna
Intest Res 2021;19(3):265-274.   Published online August 18, 2020
DOI: https://doi.org/10.5217/ir.2020.00045
AbstractAbstract PDFPubReaderePub
Inflammatory bowel disease (IBD) is a common diarrheal illness with gastrointestinal and extraintestinal manifestations and complications. The most common infectious complication associated with IBD is Clostridioides difficile infection (CDI). Active IBD predisposes to CDI due to alterations in the gut microbiome. C. difficile is a toxin producing bacterium leading to worsening of underlying IBD, increasing the risk of IBD treatment failure and an increased risk of hospitalization and surgery. Since the symptoms of CDI overlap with those of an IBD flare; it is prudent to recognize that the diagnosis of CDI is challenging and diagnostic tests (nucleic-acid and toxin-based assays) should be interpreted in context of symptoms and test performance. First line treatments for management of CDI in IBD include vancomycin or fidaxomicin. Recurrence prevention strategies should be implemented to mitigate recurrent CDI risk. One needs to monitor IBD disease progression and manage immunosuppression. The risk of recurrent CDI after a primary infection is higher in IBD compared to non-IBD patients. Microbiota restoration therapies are effective to prevent recurrent CDI in IBD patients. This review summarizes the epidemiology, pathophysiology, diagnostic testing, outcomes and management of both CDI and IBD, in CDI complicating IBD.

Citations

Citations to this article as recorded by  
  • Special Issue “Bacterial Toxins and Cancer”
    Sara Travaglione, Francesca Carlini, Zaira Maroccia, Alessia Fabbri
    International Journal of Molecular Sciences.2024; 25(4): 2128.     CrossRef
  • 19-Year-Old Man With Abdominal Pain, Vomiting, Bloody Diarrhea, and Rash
    David L. Farrier, David Chiang, Amindra S. Arora
    Mayo Clinic Proceedings.2024; 99(6): 980.     CrossRef
  • Pharmacological effects of ginseng and ginsenosides on intestinal inflammation and the immune system
    Linxian Zhao, Tongbo Zhang, Kai Zhang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Clostridioides difficile infection in inflammatory bowel disease: a clinical review
    Mengjun Tang, Chunhua Wang, Ying Xia, Jian Tang, Jiao Wang, Liang Shen
    Expert Review of Anti-infective Therapy.2024; 22(5): 297.     CrossRef
  • Management of Clostridioides difficile infection: an Italian Delphi consensus
    Matteo Bassetti, Antonio Cascio, Francesco Giuseppe De Rosa, Marianna Meschiari, Roberto Parrella, Nicola Petrosillo, Alessandro Armuzzi, Flavio Caprioli, Francesco Dentali, Marcello Pani, Alberto Pilotto, Umberto Restelli, Maurizio Sanguinetti
    Journal of Antimicrobial Chemotherapy.2024; 79(9): 2103.     CrossRef
  • Treatment outcomes of mild to moderate Clostridioides difficile infection in inflammatory bowel disease: an Australian experience
    Rachael Jacob, Virginia Chu, Watson Ng, Astrid‐Jane Williams, Susan Connor
    Internal Medicine Journal.2024; 54(12): 2009.     CrossRef
  • Clinical outcomes for Clostridioides difficile associated diarrhea in inflammatory bowel disease patients versus non-IBD population: A retrospective cohort study
    Genady Drozdinsky, Alaa Atamna, Hagar Banai, Haim Ben-Zvi, Jihad Bishara, Noa Eliakim-Raz
    Medicine.2023; 102(6): e32812.     CrossRef
  • Clostridioides difficile Toxin B Induced Senescence: A New Pathologic Player for Colorectal Cancer?
    Katia Fettucciari, Alessandro Fruganti, Fabrizio Stracci, Andrea Spaterna, Pierfrancesco Marconi, Gabrio Bassotti
    International Journal of Molecular Sciences.2023; 24(9): 8155.     CrossRef
  • Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: A retrospective cohort study from northern India
    Sandeep Mundhra, David Thomas, Saransh Jain, Pabitra Sahu, Sudheer Vuyyuru, Peeyush Kumar, Bhaskar Kante, Rajesh Panwar, Peush Sahni, Rama Chaudhry, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Indian Journal of Gastroenterology.2023; 42(3): 411.     CrossRef
  • Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
    Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease
    Andree H Koop, Paul M Travers, Sahil Khanna, Darrell S Pardi, Francis A Farraye, Jana G Hashash
    Journal of Gastroenterology and Hepatology.2023; 38(11): 1910.     CrossRef
  • Clostridioides difficile Infection in Inflammatory Bowel Disease Patients: A Systematic Review of Risk Factors and Approach in Management
    Leslie Sangurima, Maujid Masood Malik, Nency Ganatra, Rosemary Siby, Sanjay Kumar, Sara Khan, Doju Cheriachan, Lubna Mohammed
    Cureus.2023;[Epub]     CrossRef
  • Role of the Alteration in Calcium Homeostasis in Cell Death Induced by Clostridioides difficile Toxin A and Toxin B
    Katia Fettucciari, Fabrizio Dini, Pierfrancesco Marconi, Gabrio Bassotti
    Biology.2023; 12(8): 1117.     CrossRef
  • Gut Microbiota Associated with Clostridioides difficile Carriage in Three Clinical Groups (Inflammatory Bowel Disease, C. difficile Infection and Healthcare Workers) in Hospital Field
    Elisa Martinez, Sebastien Crevecoeur, Carine Thirion, Jessica Grandjean, Papa Abdoulaye Fall, Marie-Pierre Hayette, Moutschen Michel, Bernard Taminiau, Edouard Louis, Georges Daube
    Microorganisms.2023; 11(10): 2527.     CrossRef
  • Prevalence of Clostridium Difficile Infection (CDI) among Inflammatory Bowel Disease (IBD) Patients in Comparison to Non-IBD Patients in King Abdulaziz Medical City in Jeddah
    Ghassan Abdulrahman Sukkar, Syed Sameer Aga, Abdulrahman Hamid Alsamadani, Faisal Ghazi Almalki, Ali Saleh Alsudais, Abdulrahman Sulaiman Alquzi, Mohamed Eldigire Ahmed, Mushtaq Ahmad Mir, Moudi M. Alasmari, Shivendra Singh
    Interdisciplinary Perspectives on Infectious Diseases.2023; 2023: 1.     CrossRef
  • Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis
    Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Joon Seop Lee, Sung Kook Kim, Yun Jin Jung, Sang-Bum Kang, Manasi Agrawal, Ryan Ungaro, Jean-Frederic Colombel
    Digestive Diseases and Sciences.2022; 67(7): 2866.     CrossRef
  • Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis
    Sheng-Bo Fang, Yan-Qing Song, Chun-Yan Zhang, Li-Bo Wang
    World Journal of Pediatrics.2022; 18(1): 27.     CrossRef
  • Clostridium innocuum infection in hospitalised patients with inflammatory bowel disease
    Puo-Hsien Le, Cheng-Tang Chiu, Pai-Jui Yeh, Yu-Bin Pan, Cheng-Hsun Chiu
    Journal of Infection.2022; 84(3): 337.     CrossRef
  • Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics
    Quan Lu, Mei-feng Yang, Yu-jie Liang, Jing Xu, Hao-ming Xu, Yu-qiang Nie, Li-sheng Wang, Jun Yao, De-feng Li
    Journal of Inflammation Research.2022; Volume 15: 1825.     CrossRef
  • Clostridioides Infection in Patients with Inflammatory Bowel Disease
    Mi Rae Lee, Eun Soo Kim
    The Korean Journal of Gastroenterology.2022; 80(2): 66.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Exploration of Potential Gut Microbiota-Derived Biomarkers to Predict the Success of Fecal Microbiota Transplantation in Ulcerative Colitis: A Prospective Cohort in Korea
    Gi-Ung Kang, Sowon Park, Yeongyun Jung, Jai J. Jee, Min-Sueng Kim, Seungjun Lee, Dong-Woo Lee, Jae-Ho Shin, Hong Koh
    Gut and Liver.2022; 16(5): 775.     CrossRef
  • Do We Have an Opportunity to Avoid Opportunistic Infections in Asian Patients with Inflammatory Bowel Disease?
    Suhyun Park, Sang Hyoung Park
    Gut and Liver.2022; 16(5): 663.     CrossRef
  • Microbial Modulation in Inflammatory Bowel Diseases
    Jongwook Yu, Jae Hee Cheon
    Immune Network.2022;[Epub]     CrossRef
  • Using next-generation sequencing to develop a Shigella species threshold and profile faecal samples from suspected diarrhoea cases
    Ann Smith
    Folia Microbiologica.2021; 66(3): 399.     CrossRef
  • Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection
    Sarah Rotondo‐Trivette, Beibei Wang, Christopher Gayer, Riddhi Parsana, Yihui Luan, Fengzhu Sun, Sonia Michail
    Alimentary Pharmacology & Therapeutics.2021; 54(6): 792.     CrossRef
  • Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease May be Favoured by the Effects of Proinflammatory Cytokines on the Enteroglial Network
    Gabrio Bassotti, Alessandro Fruganti, Giovanni Maconi, Pierfrancesco Marconi, Katia Fettucciari
    Journal of Inflammation Research.2021; Volume 14: 7443.     CrossRef
  • 15,588 View
  • 622 Download
  • 26 Web of Science
  • 27 Crossref
Close layer
Brief Communication
Miscellaneous
Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings
Janice M. Cho, Laura Pestana, Ryan Pardi, Darrell S. Pardi, Sahil Khanna
Intest Res 2019;17(3):434-437.   Published online May 31, 2019
DOI: https://doi.org/10.5217/ir.2019.00056
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection
    Whitfield L. Knapple, David S. Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies
    Muthukumaran Jayachandran, Shen Qu
    Reviews in Endocrine and Metabolic Disorders.2023; 24(6): 1189.     CrossRef
  • Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease
    Raseen Tariq, Molly B Disbrow, John K Dibaise, Robert Orenstein, Srishti Saha, Dipesh Solanky, Edward V Loftus, Darrell S Pardi, Sahil Khanna
    Inflammatory Bowel Diseases.2020; 26(9): 1415.     CrossRef
  • Faecal Microbiota Transplantation is Effective for the Initial Treatment of Clostridium difficile Infection: A Retrospective Clinical Review
    Niloufar Roshan, Annabel K. Clancy, Thomas J. Borody
    Infectious Diseases and Therapy.2020; 9(4): 935.     CrossRef
  • 5,680 View
  • 99 Download
  • 5 Web of Science
  • 4 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP